Company intelligence / Profile preview

Arletta Pharma Solutions

Amsterdam, North Holland, Netherlands

Ownership: Private
Employees: ~9
Development stage: Other

Overview

Arletta Pharma Solutions is a clinical-stage pharmaceutical company based in Amsterdam, specializing in innovative therapies for women's sexual health. The company's lead asset, Lybrido™, is an on-demand, dual-action oral therapy designed to treat Female Sexual Interest/Arousal Disorder (FSIAD) and Hypoactive Sexual Desire Disorder (HSDD). Lybrido™ combines a sublingual testosterone coating with a sildenafil core to address both the psychological and physiological components of sexual dysfunction. Arletta is currently advancing toward pivotal Phase 3 trials in Europe and the United States, building on over fifteen years of scientific research.

Therapeutic areas: Women's Health
Modalities: Small molecule
Industry: Biotech

Partnerships

CR2OEmotional Brain

Beyond the preview

Go deeper on Arletta Pharma Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arletta Pharma Solutions.

Explore the full profile